Most ovarian cancers are diagnosed in postmenopausal women, with the average age of onset falling in the mid-fifties to early sixties depending on the tumor type and the population studied. For the most common form, high-grade serous ovarian cancer, one large multicenter study found a mean age of onset of about 55 years. But that single number hides enormous variation: certain hereditary mutations shift the typical diagnosis a decade earlier, particular tumor subtypes strike teenagers, and racial disparities alter the age distribution in ways researchers are still working to explain.
Why the “Typical” Age Depends on Which Ovarian Cancer You Mean
Ovarian cancer is not a single disease. It is a collection of tumor types with different cells of origin, different molecular drivers, and very different age profiles. The most common type by far is high-grade serous carcinoma, which accounts for the majority of epithelial ovarian cancers and tends to appear in women well past their reproductive years. A study across multiple European and Asian centers put the mean age of onset for high-grade serous cancers at about 55 years, with a standard deviation of roughly ten years, meaning that most patients were diagnosed somewhere between their mid-forties and mid-sixties.1International Journal of Gynecological Cancer. Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients
Clear cell carcinoma, another epithelial subtype, tends to show up earlier. Women diagnosed with clear cell tumors are generally younger and more likely to be caught at an early stage compared with those who have high-grade serous disease.2PubMed. Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes Clear cell carcinomas are relatively uncommon in Western populations but make up a larger share of ovarian cancers in East Asian countries, which partly explains why the average age at diagnosis can look different across regions.
The starkest age difference comes from malignant ovarian germ cell tumors. These are rare cancers that arise from the egg-producing cells themselves, and they overwhelmingly affect young women and girls. One study of reproductive-age patients found a median age of 24 years, with a range stretching down to 9.3PubMed Central. Germinal ovarian tumors in reproductive age women: Fertility-sparing and outcome A separate study specifically looking at pediatric and adolescent patients with these tumors reported a median age of just 12, with the youngest patient being 6.4PubMed. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors These tumors are biologically distinct from the epithelial cancers that dominate in older women, and their treatment and prognosis are also different. The good news is that germ cell tumors are generally more responsive to chemotherapy and have higher cure rates, and fertility-sparing surgery is often possible.
How Inherited Mutations Pull the Age of Diagnosis Earlier
Carrying a BRCA1 or BRCA2 gene mutation is the single strongest known genetic risk factor for ovarian cancer, and it shifts the expected age of onset considerably. In a landmark study from the New England Journal of Medicine, women with BRCA1 mutations who developed ovarian cancer had an average age at diagnosis of 48, with cases appearing as young as 28.5PubMed. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1 More recent data from a Japanese cohort found average ages of about 51 for BRCA1 carriers and 58 for BRCA2 carriers, compared with roughly 54 for women without either mutation. Notably, no BRCA2 carriers in that study developed ovarian cancer before age 40.6PubMed Central. Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy
Even within BRCA carriers, the specific type of mutation matters. A large European analysis found that patients with nonsense mutations (the type that completely stops a protein from being made) developed high-grade serous ovarian cancer earlier than those with frameshift mutations (the type that scrambles the protein’s instructions). Among BRCA1 carriers, that gap was about three years on average; among BRCA2 carriers, it was about five years.1International Journal of Gynecological Cancer. Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients This kind of granularity is increasingly relevant because the timing of preventive surgery, specifically the removal of the fallopian tubes and ovaries, can be tailored to the patient’s specific mutation rather than relying on a one-size-fits-all age recommendation.
Lynch syndrome, a hereditary condition that increases the risk of several cancers including colorectal and endometrial cancers, also raises ovarian cancer risk and shifts onset earlier. A systematic review of Lynch syndrome-associated ovarian cancer found a mean age at diagnosis of about 45.7PubMed. Ovarian cancer in Lynch syndrome; a systematic review A separate analysis looking at specific mismatch repair genes found a median diagnosis age of 47, though women with certain mutation types (truncating versus nontruncating) differed by about six years.8JAMA Oncology. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies Lynch-associated ovarian cancers tend to be diagnosed at earlier stages than sporadic cases and are more often of the endometrioid or clear cell subtype rather than the serous subtype.
What Reproductive History Has to Do With It
Two longstanding theories link ovarian cancer risk to reproductive biology. The “incessant ovulation” hypothesis suggests that each ovulation cycle creates minor trauma to the ovarian surface, accumulating damage over decades. The gonadotropin stimulation hypothesis focuses on the hormones that drive ovulation and their potential to promote abnormal cell growth.9PubMed Central. Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion Both theories predict that anything reducing the total number of lifetime ovulations, such as pregnancy, breastfeeding, or oral contraceptive use, should lower risk. And broadly, that is what the data show, though the picture is more complicated than either theory alone would predict.
A large pooled analysis found that the protective effects of pregnancy and oral contraceptive use were stronger than you would expect from ovulation suppression alone. One year of pregnancy, for instance, reduced risk more than one year on the pill, even though both prevent ovulation. This suggests that hormonal changes during pregnancy, not just the absence of ovulation, play an independent protective role.10JNCI: Journal of the National Cancer Institute. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
When you look at the other end of the reproductive timeline, the age you started menstruating and the age you stop both affect risk. A meta-analysis found that later menarche was associated with about a 15% lower risk of ovarian cancer compared with early menarche.11PubMed Central. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies A 2025 study looking specifically at women over 40 found that early menarche (at 12 or younger) was associated with roughly 37% higher risk in premenopausal women, and that late menopause (at 55 or later) also raised risk. Women whose total reproductive span, from first period to menopause, lasted 40 years or longer had about a 21% higher risk.12JAMA Network Open. Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older In practical terms, a longer window of active ovulation translates to more cumulative exposure to the biological processes that can initiate cancer.
Oral Contraceptives and Hormone Replacement Therapy Push Risk in Opposite Directions
Oral contraceptive use is one of the most consistently identified protective factors. A large collaborative reanalysis of 45 studies across 21 countries confirmed the association between pill use and lower ovarian cancer risk.13The Lancet. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies in 21 countries This protection holds even for women with BRCA mutations: among carriers, each year of oral contraceptive use reduced risk by about 5%, and six or more years of use was associated with a roughly 38% lower risk.14PubMed Central. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations An interesting detail is that the pill’s protective effect appears to persist into old age without weakening, while the protective effect of having had children (parity) tends to fade after 75.15PubMed Central. Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women
Hormone replacement therapy after menopause moves the needle the other way. A collaborative reanalysis of 52 studies found that women who had ever used HRT had about a 20% higher risk of ovarian cancer. Risk was greatest among current users and decreased after stopping, but women who had used HRT for at least five years and then quit were still at slightly elevated risk more than five years later.16The Lancet. Ovarian cancer and hormone replacement therapy: collaborative reanalysis of data from 52 epidemiological studies participating in the Collaborative Group on Epidemiological Studies of Ovarian Cancer A more recent meta-analysis found similar numbers, with cohort studies reporting about a 20% increase and case-control studies about a 13% increase in risk among HRT users.17PubMed Central. The risk of ovarian cancer in hormone replacement therapy users: a systematic review and meta-analysis The type of HRT may matter, too: one study of postmenopausal women with endometriosis found that estrogen-only therapy carried a substantially higher risk than combined estrogen-progesterone formulations.18PubMed Central. Impact of Hormone Replacement Therapy on Risk of Ovarian Cancer in Postmenopausal Women with De Novo Endometriosis or a History of Endometriosis
Racial Differences in Age at Diagnosis and Survival
In the United States, Black women with epithelial ovarian cancer are more likely to be diagnosed at a younger age than White women. An analysis of national cancer registry data found that about 27% of Black women were newly diagnosed before age 55, compared with about 25% of White women.19PubMed Central. Health Disparities in Ovarian Cancer Report From the Ovarian Cancer Evidence Review Conference The gap may seem modest in percentage terms, but in a disease that is already difficult to catch early, any shift in the age distribution has practical implications for who gets screened, who gets genetic counseling, and when clinicians start considering ovarian cancer as part of a differential diagnosis for pelvic symptoms.
The disparities extend beyond diagnosis. Black women with ovarian cancer have significantly worse survival than White women, even after adjusting for stage at diagnosis and treatment. A recent study found that Black women had about a 45% higher hazard of death overall. Accounting for neighborhood-level socioeconomic disadvantage reduced that gap somewhat but did not close it, and the interaction between race and living in a disadvantaged area was worse than what either factor alone would predict.20JAMA Network Open. Residential Context and Survival Disparities in Black and White Women With Ovarian Cancer These findings point to a tangle of biological, socioeconomic, and healthcare-access factors that researchers have not yet fully untangled.
Why Diagnosis Works Differently Before and After Menopause
The blood tests used to evaluate a suspicious pelvic mass do not perform equally across age groups, and this directly relates to the age-of-onset question. CA-125, the most widely used ovarian cancer biomarker, is elevated in many non-cancerous conditions common in younger women, including endometriosis, fibroids, and even normal menstruation. This makes it less specific in premenopausal patients. A meta-analysis found that HE4, a newer biomarker, had notably higher specificity than CA-125 in premenopausal women, while CA-125 and the ROMA algorithm (which combines both markers with menopausal status) performed better in postmenopausal patients.21PubMed. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis A separate study confirmed that in premenopausal women, combining CA-125 and HE4 with age yielded the best diagnostic accuracy, while in postmenopausal women, ROMA alone performed well.22PubMed Central. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer
If you are premenopausal and a doctor orders a CA-125 test for a pelvic mass, a mildly elevated result is less alarming than it would be in a postmenopausal woman. That does not mean ovarian cancer is impossible at a younger age, just that the test is less useful on its own. Clinicians working up a mass in a younger woman will typically lean more heavily on imaging and clinical context than on a single blood marker.
The Screening Problem
Given that most ovarian cancers are diagnosed at an advanced stage and that earlier detection would theoretically improve survival, you might expect population-wide screening to have been adopted by now. It has not, and a very large trial is the main reason. The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized more than 200,000 postmenopausal women into three groups: annual screening with a multimodal blood-test strategy, annual ultrasound screening, or no screening. After long-term follow-up, neither screening approach led to a statistically significant reduction in ovarian cancer deaths.23PubMed Central. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial The multimodal strategy did detect more cancers at earlier stages, but that stage shift did not translate into fewer deaths, which is the outcome that matters. As a result, no major medical organization currently recommends routine ovarian cancer screening for women at average risk, regardless of age.
For high-risk women, those with known BRCA mutations or Lynch syndrome, the conversation is different. Genetic counseling and risk-reducing surgery are the primary strategies, and the timing of that surgery is increasingly guided by the specific mutation a woman carries rather than a blanket age threshold.
Falling Incidence Rates in the United States
One piece of good news: ovarian cancer rates in the United States have been declining for decades. An analysis using data from 1975 to 2018 found that the age-standardized incidence rate for the total population dropped from roughly 8.7 per 100,000 in 1975 to about 4.8 per 100,000, with the steepest decline occurring after 2015.24PubMed Central. Ovarian cancer disease burden decreased in the United States from 1975 to 2018: A joinpoint and age-period-cohort analysis Widespread oral contraceptive use is thought to be a major contributor to this trend, along with increasing rates of surgical sterilization and, more recently, opportunistic removal of fallopian tubes during pelvic surgeries performed for other reasons. The pattern is not universal, though. In some developing countries, incidence appears to be rising, particularly in middle-aged and older women, likely reflecting demographic shifts and changes in reproductive patterns.25PubMed. Changing trends in incidence of ovarian cancer – the Indian scenario
How Age Shapes Treatment and Outcomes
Older women with ovarian cancer face a double disadvantage. They are more likely to be diagnosed at an advanced stage, and they are less likely to receive the full standard treatment. A study examining treatment patterns found that being 70 or older independently predicted a lower chance of receiving surgery and standard chemotherapy, even after accounting for other health conditions.26PubMed. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients When older women did receive standard chemotherapy, however, age alone was no longer a significant predictor of worse outcomes; it was underlying health conditions, not the calendar year on the birth certificate, that drove the poorer prognosis. A more recent analysis found that five-year overall survival was about 67% for patients under 70 compared with about 44% for those 70 and older.27PubMed Central. Influence of Age on Treatment and Prognosis in Ovarian Cancer Patients
The takeaway here is that the survival gap in older patients is not purely biological. Part of it is driven by clinical decisions, sometimes appropriate and sometimes not, to offer less aggressive treatment. For a fit 72-year-old with no major comorbidities, the conversation about treatment should look very different from the one had with a frail 72-year-old with heart failure, even though both fall on the same side of the age cutoff.
An Unexpected Animal Model
One of the more surprising parallels in ovarian cancer research involves domestic chickens. Laying hens are the only non-human animals that develop spontaneous ovarian cancer at appreciable rates, and the similarities to human disease are striking. Depending on age, genetic strain, and laying history, the prevalence in hens can range from 5% to 35%. The tumors share histological subtypes with human ovarian cancer, including high-grade serous, and display some of the same molecular features, such as CA-125 expression and p53 mutations.28PubMed Central. The chicken model of spontaneous ovarian cancer The connection makes intuitive sense once you consider that hens ovulate almost daily, racking up a number of ovulations in a few years that would take a human woman decades to match. The hen model has become a valuable tool for studying the early molecular events in ovarian cancer and testing prevention strategies in a way that would take decades to study in human populations.